GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (NSE:SUVEN) » Definitions » Debt-to-Revenue

Suven Life Sciences (NSE:SUVEN) Debt-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Suven Life Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Suven Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.00 Mil. Suven Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.00 Mil. Suven Life Sciences's annualized Revenue for the quarter that ended in Dec. 2024 was ₹64.40 Mil. Suven Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.


Suven Life Sciences Debt-to-Revenue Historical Data

The historical data trend for Suven Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Debt-to-Revenue Chart

Suven Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.35 0.27 0.12 0.06

Suven Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.07 - 0.02 -

Competitive Comparison of Suven Life Sciences's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Debt-to-Revenue falls into.


;
;

Suven Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Suven Life Sciences's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(7.097 + 0) / 116.929
=0.06

Suven Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 64.396
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Suven Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines